A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs BMS 986012 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 10 Dec 2018 Planned End Date changed from 17 Oct 2018 to 24 Oct 2019.
- 10 Dec 2018 Planned primary completion date changed from 16 Oct 2018 to 23 Oct 2019.
- 29 Dec 2017 Planned End Date changed from 16 Sep 2018 to 17 Oct 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History